FDA’s Peripheral & CNS Drugs Advisory Committee
Executive Summary
Carter-Wallace's anti-epileptic Felbatol (felbamate) will be reviewed Dec. 14. On Dec. 15, the committee will review another epilepsy agent, Warner-Lambert's Neurotonin (gabapentin). Carter- Wallace filed an NDA (20-189) for Felbatol on Sept. 30, 1991; Warner-Lambert filed its NDA (20-235) in January. The meeting begins at 8 a.m. both days at the Holiday Inn-Bethesda, 8120 Wisconsin Avenue, Bethesda, Md.